NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III ...
NeuroVive Pharmaceutical AB (publ) has completed the rights issue approved by an Extraordinary General Meeting on 13 December 2013. The subscription period was 13-27 January 2014. The rights issue was ...
Agreement expands consulting services acquired by NeuroVive, with the possibility of a broader partnership for development and commercialization services.
One of NeuroVive's largest shareholders, Baulos Capital (formerly Private Placement Sprl) and Dr. Guo Weicheng, co-founder of Sihuan Pharmaceuticals (the company's partner in China) have undertaken to ...
NeuroVive Pharmaceutical AB (publ) today announced that 22 January 2014 is the last day of trading in subscription rights in the company's ongoing new issue. The subscription period will continue unti ...
On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to execute a rights issue. Coincident with this new share issue, NeuroVive has published a prosp ...
The private placement reported to the market on 20 November 2013 and approved by the Extraordinary General Meeting (EGM) on 13 December 2013 is now complete.
On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majori ...
The news release of 20 November at 5:55 p.m. stated the subscription period for the Rights Issue as 13-27 January 2013. The correct dates should be 13-27 January 2014.
Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Read our cookie policy